David McElligott, Ph.D.
Chief Scientific Officer
Dr. David McElligott joined Petra after serving as Accelerator’s Chief Scientific Officer since 2012. Previously, he served as the founding Chief Scientific Officer at Groove Biopharma, a microRNA therapeutics company, where he was responsible for leading the spin-out of the technology from Nanogen (now part of ELITech Group). Prior to founding Groove Biopharma, Dr. McElligott served as Senior Director of Biological Sciences at ICOS Corp. where he led numerous preclinical drug discovery projects in oncology, inflammation, and urology. Several of those projects led to successful IND filings and clinical development programs. Before joining ICOS in 1997, Dr. McElligott held academic appointments in the Department of Immunology at The Scripps Research Institute and The Salk Institute for Biological Sciences. Dr. McElligott received his Ph. D. and B.S degrees in Microbiology/Immunology from the University of Iowa. He also serves on the advisory boards of the NYU Innovation Venture Fund and Rockefeller University’s newly-established Robertson Therapeutic Development Fund.